At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 40 enrolled
Drug / intervention
florbetapir F 18drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of Physician Training for Interpretation of Florbetapir-PET Scans: Evaluation of Inter-reader Reliability Using Images From Subjects With a Clinical Presentation of AD or MCI
In Brief
A Phase 3 clinical trial evaluating florbetapir F 18 for Alzheimer's Disease. Completed, enrolled 40 participants.
Detailed Summary
Re-read of brain amyloid scans acquired in previous AV-45 clinical studies by readers trained using updated reading methodology. The scans in this study came from subjects who had Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2011
Primary CompletionFeb 2011
First PostedMar 2012
TodayJul 2026
First PostedMar 28, 2012
Enrollment StartFeb 1, 2011
Primary CompletionFeb 1, 2011
TodayJul 2, 2026
Enrollment to primary: 0 daysPosted 14.3 years ago
Interventions
florbetapir F 18drug
IV injection, 370MBq (10mCi), single dose (intervention for Study A05 participants, source of scans for this study)